What’s the Mystery Behind Kali Inc (OTCMKTS:KALY)?

January 19, 2019 -- By James Hudson -- Original Source: Oracledispatch

Shares of Kali Inc (OTCMKTS:KALY) have been a real mystery to the trading world, seemingly coming out of nowhere back in December to mount 3x gains on strong volume. The story here is about a partnership and a move into the CBD space. And to further develop that story, the company just announced a new 25 mg CBD Extract formulation for beverage infusion.

According to the release, “KALY owns and manages a patented cannabis extraction process. PURA has licensed the KALY patent for beverage infusion. PURA currently produces EVERx CBD Sports Water infused with 10 mg of CBD. Together KALY and PURA are designing a new private labeled CBD infused beverage for Generex Biotechnology, Inc. (OTCBB: GNBT). In response to feedback from PURA’s EVERx distributors, KALY and PURA are now working together to refine a new 25 mg CBD extract formulation.”

Kali Inc (OTCMKTS:KALY) trumpets itself as a developer and owner of a patented cannabis extraction process – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”

This came about on November 15, 2018, with the acquisition of NCM Biotech.

With the patented intellectual property (IP), to include the existing and ongoing research and development acquired from NCM Biotech, Kali now focuses on the development of pharmaceuticals to treat various illnesses, diseases and chronic pain as a symptom of various diagnoses. Kali also concentrates on the development of health and wellness therapies.

NCM Biotech (acquired by Kali-Extracts) in collaboration with Beech Tree Labs, Inc. (BTL) of Providence, Rhode Island, conducted a series of in vitro genomic experiments to evaluate the potential of cannabis extracts derived from KALY’s patented extraction process in the treatment of respiratory diseases. The experiments were designed to evaluate pure cannabis extracts and cannabis extracts in combination with other therapies in the treatment of chronic obstructive pulmonary disease (COPD) and Asthma. There are a significant number of genes associated with COPD and Asthma. The experiments evaluated the ability of various formulations to change Asthma or COPD associated gene expressions in human small airway epithelial cells. A cannabis extract alone demonstrated remarkable activity in gene arrays by up- or down-regulating individual genes by as much as 200-fold. Genes appearing especially sensitive to the introduction of cannabis extract were associated with inflammation, healing and cancer inhibition. Results from this series of experiments provided a baseline for comparison with data from subsequent studies.

In addition, KALY has entered into a joint venture agreement named US Cannabis Health with Puration, Inc. (USOTC: PURA), and Nouveau Pharmaceuticals, Inc. (USOTC: NOUV) to combine their respective resources for the specific purpose of developing partnerships with major pharmaceutical companies to produce medical cannabis therapies.

As noted above, KALY just announced a new 25 mg CBD Extract formulation for beverage infusion. In all, we’ve witnessed 5% tacked on to share pricing for the stock in the past week. Furthermore, the name has benefitted from a jump in recent trading volume to the tune of 47% beyond its prior sustained average level.

“Through the retail outlets our distributors serve, we are getting feedback that there is an unserved demand for CBD infused beverages with 25 mg of CBD,” said Brian Shible, CEO of PURA.

“Not many beverages even have the 10 mg concentration we currently deliver. Next to no beverage comes with 25 mg. We believe we can deliver 25 mg and still maintain our clean refreshing taste. We are considering introducing this first 25 mg beverage exclusively under the Generex label.”

At this time, carrying a capital value in the market of $16.19M, KALY has virtually no cash on the books, which compares with about $185K in total current liabilities. KALY is pulling in trailing 12-month revenues of $119K. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 205.1%. This is an exciting story, and we look forward to a follow-up chapter as events transpire. Sign-up for continuing coverage on shares of $KALY stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $KALY, either long or short, and we have not been compensated for this article.

Original Source: Oracledispatch

Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Mar 2024 to Apr 2024